知名药企，突然暴涨超115%！

Market Overview - The Hong Kong stock market saw all three major indices rise on September 15, with the Hang Seng Index up 0.22% to 26,446.56 points, the Hang Seng Tech Index up 0.91% to 6,043.61 points, and the Hang Seng China Enterprises Index up 0.21% to 9,384.76 points [1] - The total market turnover was HKD 290.2 billion, with net purchases from southbound funds amounting to HKD 14.47 billion [1] Stock Performance - Among the Hang Seng Index constituents, 33 stocks rose while 52 fell. WuXi Biologics increased by 6.47%, Li Auto by 4.56%, and Nongfu Spring by 4.11%, leading the blue-chip gains [2] - Notable stock movements included Alibaba, which saw a turnover of HKD 22.6 billion and rose by 2.32%, and Tencent, which had a turnover of HKD 10.54 billion and remained flat [4] Biotech Sector Surge - The stock of药捷安康 (Pharmaron) skyrocketed by 115.58% to HKD 415.00 per share, following the announcement of a Phase II clinical trial for its core product, TT-00420, for breast cancer treatment [5][9] - Over four trading days, Pharmaron's stock price surged nearly 500%, significantly boosting the 18A biotech sector, which rose by 15.63% overall [9] - Other biotech stocks also experienced substantial gains, including Brainstorm Cell Therapeutics up 34.93%, MIRXES up 25.91%, and Clover Biopharmaceuticals up 18.67% [9][10] New Energy Vehicle Sector Growth - The new energy vehicle industry saw significant gains, with CATL rising by 7.44% to a new high, Li Auto up 4.56%, NIO up 3.53%, and BYD up 3.44% [11] - The growth was supported by a recent initiative from eight government departments to stabilize the automotive industry, which included a payment guideline for suppliers [11][18]